Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.

Journal of virology - 1 Sept 2009

Parry Chris M, Kohli Arinder, Boinett Christine J, Towers Greg J, McCormick Adele L, Pillay Deenan

Abstract excerpt

Mutations can accumulate in the protease and gag genes of human immunodeficiency virus in patients who fail therapy with protease inhibitor drugs. Mutations within protease, the drug target, have been extensively studied. Mutations in gag have been less well studied, mostly concentrating on cleavage sites. A retroviral vector system has been adapted to study full-length gag, protease, and reverse transcriptase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to gag Gene Products, Human Immunodeficiency Virus

Share to HIV Infections

Share to HIV Protease Inhibitors

Share to Mutant Proteins

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 19587031
DOI: 10.1128/JVI.02356-08
PMCID: PMC2738216

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.PMID 19587031Read ↗

Three Residues in HIV-1 Matrix Contribute to Protease Inhibitor Susceptibility and Replication CapacitySemantic proximity Read ↗

Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease InhibitorsSemantic proximity Read ↗

Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.Semantic proximity Read ↗

Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.Semantic proximity Read ↗

Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.Semantic proximity Read ↗

Human Immunodeficiency Virus Gag and protease: partners in resistance.Semantic proximity Read ↗

Role of Gag in HIV Resistance to Protease InhibitorsSemantic proximity Read ↗

Amino Acid Insertions near Gag Cleavage Sites Restore the Otherwise Compromised Replication of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease InhibitorsSemantic proximity Read ↗

Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Semantic proximity Read ↗

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.Semantic proximity Read ↗

Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.